Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Multiple Myeloma" returned 20 results:


A Phase 1b Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis
Principal Investigator(s): Sundar Jagannath

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
Principal Investigator(s): Eileen Scigliano

A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
Principal Investigator(s): Luis M. Isola

A Phase I/II, Open-label, Multicenter Study of ACY-1215 administered Orally As Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Sundar Jagannath

Multicenter phase I/II study on the anti-tumor activity, safety and pharmacology of IPH 2101, a human monoclonal anti KIR, combined with lenalidomide in patients with Multiple Myeloma experiencing a first relapse
Principal Investigator(s): Sundar Jagannath

Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
Principal Investigator(s): Ajai Chari

A Phase 1 Study of ARRY-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Ajai Chari

A Phase II , Single-Center, Open Label study of Oral Panobinostat (LBH589) when administered in combination with Lenalidomide and weekly Dexamethasone in patients with multiple myeloma
Principal Investigator(s): Ajai Chari

Pilot study of recMAGE-A3 + AS15 ASCL as Consolidation for Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation
Principal Investigator(s): Hearn Jay Cho

Evaluation of pomalidomide in combination with high dose dexamethasone and oral cyclophosphamide in patients with relapsed and refractory myeloma
Principal Investigator(s): Sundar Jagannath

A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Ajai Chari

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination With An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Principal Investigator(s): Ajai Chari

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Luis M. Isola

A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
Principal Investigator(s): Luis M. Isola

A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects with Refractory, Relapsed or Relapsed/Refractory Multiple Myeloma
Principal Investigator(s): Sundar Jagannath

A Phase 2 Biomarker Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Principal Investigator(s): Sundar Jagannath

A Phase I/II open-label multicenter study of AT7519M alone and in combination with bortezomib in patients with previously treated multiple myeloma
Principal Investigator(s): Ajai Chari

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
Principal Investigator(s): Sundar Jagannath

Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
Principal Investigator(s): Luis M. Isola

Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONYX 0912 in Patients with Hematological Malignancies
Principal Investigator(s): Sundar Jagannath